Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy

Zhuming Yang, Danlei Han, Renying Ge, Zhenhao Wang, Hanlin Du, Yigang Guo, Zhe Zhao, Li Liu, Jun Qin, Bangwei Yu, Jie Hu, Xiya Gui, Meifang Su, Shiming Chen, Daozi Jiang, Jing Zheng, Hongxiang Wang, Li Meng, Weiming Li, Zhenya Hong

Open source

DOI: 10.1177/20406207261474931
Published: 2026-07
Container: Therapeutic Advances in Hematology
Publisher: SAGE Publications
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/20406207261474931,
  title = {Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy},
  author = {Zhuming Yang and Danlei Han and Renying Ge and Zhenhao Wang and Hanlin Du and Yigang Guo and Zhe Zhao and Li Liu and Jun Qin and Bangwei Yu and Jie Hu and Xiya Gui and Meifang Su and Shiming Chen and Daozi Jiang and Jing Zheng and Hongxiang Wang and Li Meng and Weiming Li and Zhenya Hong},
  year = {2026},
  journal = {Therapeutic Advances in Hematology},
  doi = {10.1177/20406207261474931},
  url = {https://doi.org/10.1177/20406207261474931}
}

RIS

TY  - JOUR
TI  - Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy
AU  - Zhuming Yang
AU  - Danlei Han
AU  - Renying Ge
AU  - Zhenhao Wang
AU  - Hanlin Du
AU  - Yigang Guo
AU  - Zhe Zhao
AU  - Li Liu
AU  - Jun Qin
AU  - Bangwei Yu
AU  - Jie Hu
AU  - Xiya Gui
AU  - Meifang Su
AU  - Shiming Chen
AU  - Daozi Jiang
AU  - Jing Zheng
AU  - Hongxiang Wang
AU  - Li Meng
AU  - Weiming Li
AU  - Zhenya Hong
PY  - 2026
JO  - Therapeutic Advances in Hematology
DO  - 10.1177/20406207261474931
UR  - https://doi.org/10.1177/20406207261474931
ER  -

APA

Yang, Z., Han, D., Ge, R., Wang, Z., Du, H., Guo, Y., Zhao, Z., Liu, L., Qin, J., Yu, B., Hu, J., Gui, X., Su, M., Chen, S., Jiang, D., Zheng, J., Wang, H., Meng, L., Li, W., & Hong, Z. (2026). Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy. Therapeutic Advances in Hematology. https://doi.org/10.1177/20406207261474931

Source records

crossref · retrieved 2026-09-26T08:44:05.986Z